These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 34245333

  • 1. Spatially-resolved pharmacokinetic/pharmacodynamic modelling of bystander effects of a nitrochloromethylbenzindoline hypoxia-activated prodrug.
    Hong CR, Mehta SY, Liyanage HDS, McManaway SP, Lee HH, Jaiswal JK, Bogle G, Tercel M, Pruijn FB, Wilson WR, Hicks KO.
    Cancer Chemother Pharmacol; 2021 Oct; 88(4):673-687. PubMed ID: 34245333
    [Abstract] [Full Text] [Related]

  • 2. Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects.
    Hong CR, Dickson BD, Jaiswal JK, Pruijn FB, Hunter FW, Hay MP, Hicks KO, Wilson WR.
    Biochem Pharmacol; 2018 Oct; 156():265-280. PubMed ID: 30134191
    [Abstract] [Full Text] [Related]

  • 3. An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect.
    Hong CR, Wilson WR, Hicks KO.
    Neoplasia; 2019 Feb; 21(2):159-171. PubMed ID: 30591421
    [Abstract] [Full Text] [Related]

  • 4. Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures.
    Hong CR, Bogle G, Wang J, Patel K, Pruijn FB, Wilson WR, Hicks KO.
    Front Pharmacol; 2018 Feb; 9():1013. PubMed ID: 30279659
    [Abstract] [Full Text] [Related]

  • 5. The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104.
    Foehrenbacher A, Patel K, Abbattista MR, Guise CP, Secomb TW, Wilson WR, Hicks KO.
    Front Oncol; 2013 Feb; 3():263. PubMed ID: 24109591
    [Abstract] [Full Text] [Related]

  • 6. Hypoxia-selective radiosensitisation by SN38023, a bioreductive prodrug of DNA-dependent protein kinase inhibitor IC87361.
    Wong WW, Jackson RK, Liew LP, Dickson BD, Cheng GJ, Lipert B, Gu Y, Hunter FW, Wilson WR, Hay MP.
    Biochem Pharmacol; 2019 Nov; 169():113641. PubMed ID: 31541630
    [Abstract] [Full Text] [Related]

  • 7. Tissue Pharmacokinetic Properties and Bystander Potential of Hypoxia-Activated Prodrug CP-506 by Agent-Based Modelling.
    Jackson-Patel V, Liu E, Bull MR, Ashoorzadeh A, Bogle G, Wolfram A, Hicks KO, Smaill JB, Patterson AV.
    Front Pharmacol; 2022 Nov; 13():803602. PubMed ID: 35211015
    [Abstract] [Full Text] [Related]

  • 8. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards.
    Wilson WR, Hicks KO, Pullen SM, Ferry DM, Helsby NA, Patterson AV.
    Radiat Res; 2007 Jun; 167(6):625-36. PubMed ID: 17523848
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954.
    Vass SO, Jarrom D, Wilson WR, Hyde EI, Searle PF.
    Br J Cancer; 2009 Jun 16; 100(12):1903-11. PubMed ID: 19455141
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling.
    Foehrenbacher A, Secomb TW, Wilson WR, Hicks KO.
    Front Oncol; 2013 Dec 27; 3():314. PubMed ID: 24409417
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids.
    Mao X, McManaway S, Jaiswal JK, Patel PB, Wilson WR, Hicks KO, Bogle G.
    PLoS Comput Biol; 2018 Oct 27; 14(10):e1006469. PubMed ID: 30356233
    [Abstract] [Full Text] [Related]

  • 17. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine.
    Hicks KO, Myint H, Patterson AV, Pruijn FB, Siim BG, Patel K, Wilson WR.
    Int J Radiat Oncol Biol Phys; 2007 Oct 01; 69(2):560-71. PubMed ID: 17869669
    [Abstract] [Full Text] [Related]

  • 18. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT.
    Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR.
    Br J Cancer; 2004 Mar 08; 90(5):1084-92. PubMed ID: 14997211
    [Abstract] [Full Text] [Related]

  • 19. Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity.
    Guise CP, Abbattista MR, Anderson RF, Li D, Taghipouran R, Tsai A, Lee SJ, Smaill JB, Denny WA, Hay MP, Wilson WR, Hicks KO, Patterson AV.
    Molecules; 2020 Oct 22; 25(21):. PubMed ID: 33105798
    [Abstract] [Full Text] [Related]

  • 20. Engineering the Escherichia coli Nitroreductase NfsA to Create a Flexible Enzyme-Prodrug Activation System.
    Sharrock AV, McManaway SP, Rich MH, Mumm JS, Hermans IF, Tercel M, Pruijn FB, Ackerley DF.
    Front Pharmacol; 2021 Oct 22; 12():701456. PubMed ID: 34163368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.